ES2878579T3 - Compuesto de fenol y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina, para el tratamiento de enfermedades de los sistemas nerviosos central y vascular - Google Patents

Compuesto de fenol y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina, para el tratamiento de enfermedades de los sistemas nerviosos central y vascular Download PDF

Info

Publication number
ES2878579T3
ES2878579T3 ES17732730T ES17732730T ES2878579T3 ES 2878579 T3 ES2878579 T3 ES 2878579T3 ES 17732730 T ES17732730 T ES 17732730T ES 17732730 T ES17732730 T ES 17732730T ES 2878579 T3 ES2878579 T3 ES 2878579T3
Authority
ES
Spain
Prior art keywords
combination
disease
treatment
vascular
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17732730T
Other languages
English (en)
Spanish (es)
Inventor
Rodriguez Estael Ochoa
Reyes Yamila Verdecia
Figueredo Yanier Nunez
Sanchez Jeney Ramirez
Guerra Maylin Wong
Fonseca Luis Arturo Fonseca
Andreu Gilberto Lázaro Pardo
Navarro Claudia Amanda Canaan-Haden
Rodriguez Abel Mondelo
Fernandez Pedro Gilberto Barzaga
Alfonso Nicté Gonzalez
Hernandez René Delgado
Yaquis Alejandro Saúl Padron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de la Habana
Centro de Investigacion y Desarrollo de Medicamentos CIDEM
Original Assignee
Universidad de la Habana
Centro de Investigacion y Desarrollo de Medicamentos CIDEM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de la Habana, Centro de Investigacion y Desarrollo de Medicamentos CIDEM filed Critical Universidad de la Habana
Application granted granted Critical
Publication of ES2878579T3 publication Critical patent/ES2878579T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
ES17732730T 2016-05-04 2017-05-03 Compuesto de fenol y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina, para el tratamiento de enfermedades de los sistemas nerviosos central y vascular Active ES2878579T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2016000059A CU24576B1 (es) 2016-05-04 2016-05-04 Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular
PCT/CU2017/050003 WO2017190714A1 (es) 2016-05-04 2017-05-03 Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular

Publications (1)

Publication Number Publication Date
ES2878579T3 true ES2878579T3 (es) 2021-11-19

Family

ID=60202803

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17732730T Active ES2878579T3 (es) 2016-05-04 2017-05-03 Compuesto de fenol y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina, para el tratamiento de enfermedades de los sistemas nerviosos central y vascular

Country Status (19)

Country Link
US (1) US10722491B2 (https=)
EP (1) EP3453704B1 (https=)
JP (1) JP6997995B2 (https=)
KR (1) KR102416478B1 (https=)
CN (1) CN109476627B (https=)
AR (1) AR108370A1 (https=)
AU (1) AU2017259749C1 (https=)
BR (1) BR112018072579B1 (https=)
CA (1) CA3023073C (https=)
CL (1) CL2018003114A1 (https=)
CO (1) CO2018011927A2 (https=)
CU (1) CU24576B1 (https=)
EA (1) EA037951B1 (https=)
ES (1) ES2878579T3 (https=)
MX (1) MX384967B (https=)
PH (1) PH12018502327A1 (https=)
SG (1) SG11201809843SA (https=)
WO (1) WO2017190714A1 (https=)
ZA (1) ZA201808161B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20160058A7 (es) 2016-05-04 2017-12-08 Centro De Investigación Y Desarrollo De Medicamentos (Cidem) Organizacion Superior De Desarrollo Emp Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular
AU2019361735A1 (en) * 2018-10-16 2021-05-27 Saban Ventures Pty Limited Apparatus and method for cleaning a medical device
CU20190114A7 (es) 2019-12-26 2021-08-06 Centro De Investig Y Desarrollo De Medicamentos Cidem Combinación para simultáneamente incrementar la eficacia analgésica de la morfina y reducir su dependencia física
BR112022012699A2 (pt) * 2019-12-26 2022-09-06 Centro De Investig Y Desarrollo De Medicamentos Cidem Uso de um derivado de benzodiazepina e método de tratamento de lesão cerebral traumática

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281714A (en) 1990-08-16 1994-01-25 American Home Products Corporation N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA: cholesterol-acyl transferase
MX9204939A (es) 1991-09-06 1993-03-01 American Home Prod Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa.
DE69202564T2 (de) 1992-07-17 1995-09-28 Biogal Gyogyszergyar Verfahren zur Herstellung von 1,3-Dioxan-4,6-Dionderivaten.
JPH11180975A (ja) 1997-10-13 1999-07-06 Chemiprokasei Kaisha Ltd アミノメチレンジオキサン誘導体、その製造方法および用途
JP5299810B2 (ja) 2004-02-27 2013-09-25 アムジエン・インコーポレーテツド 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法
JP2007063444A (ja) * 2005-08-31 2007-03-15 Tdk Corp 錯化合物及びこれを用いた光記録媒体

Also Published As

Publication number Publication date
BR112018072579A2 (pt) 2019-02-19
EP3453704B1 (en) 2021-06-16
JP2019516791A (ja) 2019-06-20
US20190133996A1 (en) 2019-05-09
AR108370A1 (es) 2018-08-15
AU2017259749A1 (en) 2018-12-20
CA3023073A1 (en) 2017-11-09
CA3023073C (en) 2022-08-30
AU2017259749B2 (en) 2021-08-19
CN109476627B (zh) 2021-06-15
EA037951B1 (ru) 2021-06-11
CU20160059A7 (es) 2017-12-08
KR20210025138A (ko) 2021-03-09
AU2017259749C1 (en) 2021-12-02
JP6997995B2 (ja) 2022-02-04
SG11201809843SA (en) 2018-12-28
EP3453704A1 (en) 2019-03-13
ZA201808161B (en) 2021-10-27
MX384967B (es) 2025-03-14
CN109476627A (zh) 2019-03-15
BR112018072579B1 (pt) 2024-02-20
CO2018011927A2 (es) 2019-02-08
EA201892462A1 (ru) 2019-07-31
KR102416478B1 (ko) 2022-07-04
CL2018003114A1 (es) 2019-06-14
US10722491B2 (en) 2020-07-28
PH12018502327A1 (en) 2019-09-02
WO2017190714A1 (es) 2017-11-09
MX2018013422A (es) 2019-08-16
CU24576B1 (es) 2022-02-04

Similar Documents

Publication Publication Date Title
ES2397746T3 (es) Métodos de administración de tetrahidrobiopterina, composiciones asociadas y métodos de medición
ES2733282T3 (es) Forma farmacéutica de dietilestilbestrol y uso para el tratamiento de cáncer de próstata o mama
ES2878579T3 (es) Compuesto de fenol y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina, para el tratamiento de enfermedades de los sistemas nerviosos central y vascular
WO2013120040A1 (en) Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy
EA025735B1 (ru) Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата
PT1901736E (pt) Composição farmacêutica compreendendo sinvastatina e ezetimiba
JP2018525388A (ja) 経口バイオアベイラビリティを有するペンタアザ大環状環錯体
US20140112983A1 (en) Nitrite compositions and uses thereof
JP2024133735A (ja) Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
ES2680643T3 (es) Compuestos antiinflamatorios
ES2288117B1 (es) Composicion farmaceutica solida de gabapentina.
JP2015507006A (ja) ユリノキの樹皮のエキスを有効成分として含有する改善された医薬製剤
ES2902992T3 (es) Derivado de benzodiazepina con actividad sobre los sistemas vascular y nervioso central
CN112912084B (zh) 芸香苷组成物
AU2011261501B2 (en) Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
WO2015112724A1 (en) Naca for the treatment of chronic or acute cognitive dysfunction
CN105169409A (zh) 普萘洛尔或其可药用盐与离子交换树脂的复合物及其混悬液
WO2015112715A1 (en) Naca for the treatment of chronic or low impact brian trauma
HK1261881A1 (en) Phenol compound and combination of same with a benzodiazepine fused to 1,4-dihydropyridine for treating diseases of the central nervous and vascular systems
HK1261881B (zh) 用於治疗中枢神经系统和血管系统的病变的酚类化合物及其与稠合於1，4-二氢吡啶的苯并二氮杂卓的组合
JP2008074838A (ja) グルコシルヘスペリジン含有組成物
HK40043982A (en) Rutin compositions
PHARMACEUTICS FORMULATION AND CHARACTERIZATION OF RIZATRIPTAN BENZOATE SUBLINGUAL TABLET WITH VARIOUS PERMEATION ENHANCERS
JP2001302549A (ja) 脂肪酸含有組成物